What's Happening?
CereVasc, Inc., a clinical-stage medical device company, has announced the successful closing of an $85 million Series C financing round. The funding, led by Piper Sandler Merchant Banking, includes participation from Johnson & Johnson Innovation and Medtronic,
along with existing investors Bain Capital Life Sciences and Perceptive Xontogeny Venture Funds. The proceeds will support the ongoing STRIDE pivotal trial and regulatory work towards FDA Premarket Approval for the eShunt System, a novel treatment for Normal Pressure Hydrocephalus. The company has also strengthened its Board of Directors with new appointments.
Why It's Important?
This financing round is a significant milestone for CereVasc, enabling the company to advance its innovative eShunt System, which aims to provide a minimally invasive treatment for neurological conditions. The investment reflects confidence in CereVasc's technology and its potential to improve patient outcomes. Successful development and commercialization of the eShunt System could offer a new standard of care for patients with Normal Pressure Hydrocephalus, reducing the need for invasive surgeries and improving quality of life.
What's Next?
CereVasc will focus on completing the STRIDE pivotal trial and preparing for FDA Premarket Approval submission. The company plans to scale up operations and move towards commercialization of the eShunt System. The strengthened Board of Directors will guide CereVasc through these critical phases, leveraging their expertise to navigate regulatory challenges and market entry strategies.
